EUVIMEDEUVIMED entdecken
LeserbriefOpen Access

Vedolizumab as a first-choice biological treatment of Crohn’s disease in a patient with paraganglioma of the nervous system

Patrycja Szałwińska, Wojciesko Ewa Malecka-

Gastroenterology Review · 2026 · 21 (1) · 108-110

DOI: 10.5114/pg.2026.160317 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Gastroenterology Review, 2026. Verfasst von Patrycja Szałwińska und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Digestive Tract Diseases, Medical University of Lodz, Poland. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Paragangliomas are rare, usually benign neuroendocrine tumours originating from the paraganglionic bodies of the parasympathetic and sympathetic nervous system, most often located at the bifurcation of the common carotid artery. Inflammatory

Autor:innen und Institutionen

  • Department of Digestive Tract Diseases, Medical University of Lodz, Poland.
  • Department of Digestive Tract Diseases, Faculty of Medicine, Medical University of Lodz, Poland.

Zitieren

APA

Szałwińska, P., & Ewa Malecka-, W. (2026). Vedolizumab as a first-choice biological treatment of Crohn’s disease in a patient with paraganglioma of the nervous system. Gastroenterology Review, 21(1), 108-110. https://doi.org/10.5114/pg.2026.160317

Vancouver

Szałwińska P, Ewa Malecka- W. Vedolizumab as a first-choice biological treatment of Crohn’s disease in a patient with paraganglioma of the nervous system. Gastroenterology Review. 2026;21(1):108-110. doi:10.5114/pg.2026.160317

BibTeX
@article{Szawiska2026,
  author = {Szałwińska, Patrycja and Ewa Malecka-, Wojciesko},
  title = {Vedolizumab as a first-choice biological treatment of Crohn’s disease in a patient with paraganglioma of the nervous system},
  journal = {Gastroenterology Review},
  year = {2026},
  volume = {21},
  number = {1},
  pages = {108--110},
  doi = {10.5114/pg.2026.160317}
}
Kostenlos starten →